An observational study in Lower Limb, Ischemia and Perfusion, sponsored by Seung-Whan Lee, M.D., Ph.D.. Completed at 1 site in Korea, Republic of. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2023-04-12.
Sponsored by Seung-Whan Lee, M.D., Ph.D. · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Chronic Limb-Threatening Ischemia with a site in Korea, Republic of — 1 open to participants now, 1 under way, none of them phase 3. Chronic Limb-Threatening Ischemia · Korea, Republic of.
Among the 11 studies in Chronic Limb-Threatening Ischemia with a site in Korea, Republic of, this one is the only one that started in 2015, is one of 3 observational ones, and was the 6th registered.
358 studies on the registry are indexed under Chronic Limb-Threatening Ischemia; 73 are open to participants now.
Browse Chronic Limb-Threatening Ischemia studies →1 of the 11 studies in Chronic Limb-Threatening Ischemia with a site in Korea, Republic of is open now. Recruiting first, the newest first:
Yonsei University · Sites in Korea, Republic of
Ages 19+
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 51 Chronic Limb-Threatening Ischemia studies recruiting now, 35 (69%) set no upper age limit and 2 (4%) stop at 75 or younger; 3 take children under 18; 6 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 3 · Phase 3 1 · Phase 4 1
First in 2006; this study’s year is marked. 1 started in 2015.
This study's enrollment of 65 is below the median of 111 across 104 observational studies indexed under Chronic Limb-Threatening Ischemia.
Median enrollment 76 across the 8 interventional studies, 100 across the 3 observational. Of the 8 that completed or were terminated, 1 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 11 have an industry lead sponsor. The 8 most frequent:
Seung-Whan Lee, M.D., Ph.D. is the lead sponsor of 5 studies on the registry; 3 are open to participants now.
Seung-Whan Lee, M.D., Ph.D. has 1 study filed under Chronic Limb-Threatening Ischemia — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 11 studies in Chronic Limb-Threatening Ischemia with a site in Korea, Republic of, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study evaluates the clinical effectiveness of Magnetic Resonance(MR) perfusion imaging to qualitatively assess adequate distal perfusion after endovascular revascularization in Critical Limb Ischemia
358 studies on the registry are indexed under Chronic Limb-Threatening Ischemia; 73 are open to participants now.
This study's enrollment of 65 is below the median of 111 across 104 observational studies indexed under Chronic Limb-Threatening Ischemia.
Browse Chronic Limb-Threatening Ischemia studies →Seung-Whan Lee, M.D., Ph.D. is the lead sponsor of 5 studies on the registry; 3 are open to participants now.
Compared within Chronic Limb-Threatening Ischemia, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Ischemia. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Patients with lower extremity ischemia
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Procedure: Magnetic Resonance Perfusion Imaging
The change of deoxyhemoglobin in MR imaging
Time frame: 6 months
The event rate of unplanned major and minor amputation in limb
Time frame: 6 months
The event rate of complete healing of lower extremity ulcer
Time frame: 6 months
Plan to share: No — This trial is not publicly funded clinical trial.
No publications or documents are linked to this record.
Ran from Dec 2015 to primary completion in Jul 2021, 67 months.
Of 47 non-industry observational studies under Chronic Limb-Threatening Ischemia, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 60. This study's 67 months is above that.
Counting every sponsor, half of 53 studies reached it within 34 months; a quarter within 22 and three quarters within 59.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chronic Limb-Threatening Ischemia →
Seung-Whan Lee, M.D., Ph.D.